AstraZeneca Enhertu Secures US FDA Approval for HER2-Low Breast Cancer

The US Food and Drug Administration (FDA) has approved Enhertu of AstraZeneca and Daiichi Sankyo for the treatment of adult patients with metastatic HER2-low breast cancer, who have received a prior chemotherapy in the metastatic setting during six months of completing adjuvant chemotherapy. Enhertu is a specifically designed HER2-directed antibody drug conjugate (ADC), that has […]

Continue Reading

Study: COVID-19 can Increase Risk of Type 2 Diabetes and Cardiovascular Diseases

According to recent studies, COVID-19 can increase the risk of both type 2 diabetes and cardiovascular disease. This has raised concerns among the scientists, who are worried about am increase in patient numbers in the future. The research, conducted by King’s College London, identified a patient’s likelihood of developing diabetes increased in three months after […]

Continue Reading